Unclaimed Scholar Profile
Are you Salome Charalambous? This profile has been curated from verified academic registries. Claim your profile to edit affiliations, manage works, and access your dashboard.
Verified ScholarVerified at University of the WitwatersrandASIDASID-1957-0060-2761 orcid.org/0000-0001-7143-1009
Salome Charalambous
University of the Witwatersrand•South Africa
Faculty researcher at University of the Witwatersrand (ZA), specializing in Agricultural, Environmental & Life Sciences. [Discipline: Agricultural, Environmental & Life Sciences] [Scholar Type: Policy & Economics Specialist] [Career Tier: Distinguished Scholar] [Region: Southern Africa]
#Tuberculosis Research and Epidemiology#HIV/AIDS Research and Interventions#Infectious Diseases and Tuberculosis#HIV/AIDS drug development and treatment
Scholarly Profiles: Google Scholar
Citation Indices
Standard Scientometrics| All | Since 2021 | |
|---|---|---|
| Citations | 7,145 | 3,430 |
| h-index | 43 | 32 |
| i10-index | 143 | 100 |
Annual Citation Growth
Verified Citations / Year0
2020343
2021+40%480
2022+29%617
2023+33%823
2024-8%755
2025-45%412
2026Scholarship Distribution & Proportions286 Articles • 0 Books & Monographs • 0 Applied Assignments
Continental Provenance:82% African Regional Citations (5,859) • 18% Global Research Impact (1,286)
286 Indexed WorksAuthentic Data
Co-Authors & Academic Collaborators
No verified co-authors registered on AfriJournal Index yet.
Browse African Scholars →Scientific Bibliography Ingestion Notice
AfriJournal Index synchronizes authentic African citations and scholarship from Crossref, OpenAlex, and verified institutional repositories. Due to external indexing latency, some historical works may not yet be ingested in this snapshot. If you are this scholar, claim this profile to link your ORCID and verify your complete bibliography.
Articles & Books (286)
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
Published in New England Journal of Medicine•2014
DOI: 10.1056/nejmoa1314210 Verified Peer-Reviewed
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Published in The Lancet Infectious Diseases•2016
DOI: 10.1016/s1473-3099(16)30274-2 Verified Peer-Reviewed
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions
Published in The Lancet Respiratory Medicine•2022
DOI: 10.1016/s2213-2600(22)00092-3 Verified Peer-Reviewed
Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa
Published in AIDS•2008
DOI: 10.1097/qad.0b013e32830e4cd8 Verified Peer-Reviewed
Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models
Published in The Lancet Global Health•2016
DOI: 10.1016/s2214-109x(16)30199-1 Verified Peer-Reviewed
Showing 1 – 5 of 286 publications
1 / 58